Suchergebnisse - "Nguyen, Bach"

PubPharm (26)

1

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Dickinson, L. | Gurjar, R. | Stöhr, W. | +113

2

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection : Week 48 Results of the DRIVE-AHEAD Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2019

von Orkin, C. | Squires, K. | Molina, J. | +15

CommentIn: Clin Infect Dis. 2019 Oct 30;69(10):1832-1833. - PMID 30891586

3

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection : Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2018

von Cahn, P. | Sax, P. | Squires, K. | +13

4

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD) : 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Molina, J. | Squires, K. | Sax, P. | +113

CommentIn: Lancet HIV. 2018 May;5(5):e200-e201. - PMID 29592841

5

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection : a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2017

von Cahn, P. | Kaplan, R. | Sax, P. | +122

CommentIn: Lancet HIV. 2017 Nov;4(11):e476-e477. - PMID 28918878

6

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial : raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

enthalten in: The Journal of antimicrobial chemotherapy | 2016

von Lambert-Niclot, S. | George, E. | Pozniak, A. | +115

7

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1 : a substudy of the NEAT001/ANRS143 randomised trial

enthalten in: The lancet. HIV | 2015

von Bernardino, J. | Mocroft, A. | Mallon, P. | +115

CommentIn: Lancet HIV. 2015 Nov;2(11):e452-3. - PMID 26520920

8

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection

enthalten in: Antiviral therapy | 2015

von Eron, J. | Cooper, D. | Steigbigel, R. | +8

9

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1 : 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

enthalten in: Lancet (London, England) | 2014

von Raffi, F. | Babiker, A. | Richert, L. | +117

CommentIn: Lancet. 2014 Nov 29;384(9958):1908-10. - PMID 25103175

10

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies : final results of two randomised, placebo-controlled trials

enthalten in: The Lancet. Infectious diseases | 2013

von Eron, J. | Cooper, D. | Steigbigel, R. | +116

CommentIn: Lancet Infect Dis. 2013 Jul;13(7):561-2. - PMID 23664332